A Phase I/II, Open-label, Multi-center Study to Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759 in Chinese Patients With EGFRm+ NSCLC With Central Nervous System (CNS) Metastases
Latest Information Update: 24 Nov 2022
At a glance
- Drugs Zorifertinib (Primary)
- Indications Brain metastases; Cancer metastases; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 20 Nov 2022 Status changed from active, no longer recruiting to completed.
- 22 Mar 2020 Planned End Date changed from 30 Jun 2020 to 30 Nov 2020.
- 22 Mar 2020 Planned primary completion date changed from 30 Jun 2020 to 30 Nov 2020.